Khiron Life Sciences Corp (CVE:KHRN) Achieves $6 Per Share Buy Rating From AltaCorp

Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH) President Chris Naprawa joins Midas Letter to discuss the recently released AltaCorp Capital research update. Senior Equity Research Analyst David Kideckel reiterated his “speculative buy” rating for the company with a price target of $6.00 – representing a return of over 200 per cent at the time of this interview.

“In our view, the market is completely discounting the value associated with Khiron’s entry into the medical cannabis product segment in other LATAM markets, which we believe is due to the regulatory uncertainty in those markets. However, we expect Khiron’s stock to revalue as the Company successfully enters into countries such as Mexico, Chile, and Brazil. There are several near-term catalysts that could drive the story, including revenues from the commercial launch of CBD in Colombia and new regulatory medical cannabis guidelines in Mexico, both of which are expected to happen in F2019,” – David Kideckel, AltaCorp Capital Senior Equity Research Analyst

Khiron’s president, though cannot speak to the forecasted numbers from three seperate analysts, believes people are starting to understand that the company is leading the way in the global cannabis business inside Latin America. Several different press releases released by the company in recent weeks support this notion. Mr. Naprawa comments on Khiron’s recently received conditional TSX-V approval for Latin American joint venture with Dixie Brands and U.S. distribution and sale of the company’s Kuida cosmeceutical line and Khiron’s move into the PGP business with SURA EPS. These pieces of news essentially allow Kuida products to expand globally with strong credibility and will allow Khiron to be able to cover cannabis with insurance in Colombia. Lastly, the Khiron Life Sciences president explains how the company’s demand in Colombia is greater than supply. The company are currently building the infrastructure to keep up with this “high” demand inside the country and also in Brazil, Uruguay plus other countries in South America.

Original article: Khiron Life Sciences Corp (CVE:KHRN) Achieves $6 Per Share Buy Rating From AltaCorp

©2019 Midas Letter. All Rights Reserved.